Amphastar Pharmaceuticals (AMPH) EBIAT: 2013-2025
Historic EBIAT for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $17.4 million.
- Amphastar Pharmaceuticals' EBIAT fell 57.09% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year decrease of 29.22%. This contributed to the annual value of $159.5 million for FY2024, which is 15.98% up from last year.
- As of Q3 2025, Amphastar Pharmaceuticals' EBIAT stood at $17.4 million, which was down 44.09% from $31.0 million recorded in Q2 2025.
- In the past 5 years, Amphastar Pharmaceuticals' EBIAT ranged from a high of $49.2 million in Q3 2023 and a low of $5.0 million during Q1 2021.
- In the last 3 years, Amphastar Pharmaceuticals' EBIAT had a median value of $36.2 million in 2023 and averaged $33.7 million.
- As far as peak fluctuations go, Amphastar Pharmaceuticals' EBIAT skyrocketed by 703.36% in 2021, and later tumbled by 57.09% in 2025.
- Over the past 5 years, Amphastar Pharmaceuticals' EBIAT (Quarterly) stood at $19.8 million in 2021, then skyrocketed by 71.62% to $33.9 million in 2022, then grew by 6.65% to $36.2 million in 2023, then increased by 4.97% to $38.0 million in 2024, then slumped by 57.09% to $17.4 million in 2025.
- Its EBIAT was $17.4 million in Q3 2025, compared to $31.0 million in Q2 2025 and $25.3 million in Q1 2025.